Overview

Genzyme Corporation is a biotechnology company dedicated to discovering and delivering transformative therapies for patients with rare and ultra-rare diseases. As a subsidiary of Sanofi, Genzyme focuses on developing therapies that can address unmet medical needs in several therapeutic areas.

Therapeutic areas

API / Drug Master Files

Genzyme Corporation holds 0 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • LEUPROLIDE ACETATEInactive1999-10-08
  • CLINDAMYCIN PHOSPHATEInactive1998-09-01
  • 5-METHYLSULFONAMIDOINDOLE-2-CARBOXYLIC ACIDInactive1994-07-21
  • SN-1-PALMITOYL-2-OLEOYLPHOSPHATIDYLGLYCEROL SODIUM SALT (POPG.NA)Inactive1994-05-25
  • SODIUM CHOLESTERYL SULPHATEInactive1993-09-30
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN LIESTAL, SWITZERLAND.Inactive1993-07-26
  • CERAMIDETRIHEXOSIDASEInactive1993-02-25
  • ACEBUTOLOL HYDROCHLORIDEInactive1992-11-10

FDA compliance signals

13 FDA enforcement records linked to this company.

  • 4832025-02-14

    No written record of investigation

  • 4832025-02-14

    Procedures are written, and followed

  • 4832025-02-14

    Examination of packaging and labeling

  • warning_letter2025-01-15

    FDA Warning Letter (drug product)

  • recall — Class III2017-11-22

    Labeling: Incorrect or Missing Package Insert.

  • 4832016-08-18

    No written record of investigation

  • 4832016-08-18

    Calibration/Inspection/Checking not done

  • 4832016-08-18

    Deviations from laboratory control requirements

  • recall — Class III2016-04-06

    Labeling: Incorrect or Missing Lot and/or Exp Date

  • recall — Class II2016-03-09

    Presence of Particulate Matter: Glass particles found in the product after reconstitution.

  • recall — Class II2016-03-09

    Presence of Particulate Matter: Glass particles found in the product after reconstitution.

  • 4832014-11-21

    Contract drug products--lack of responsibility

  • 4832014-11-21

    Contamination, chemical or physical change, deterioration

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.